's () Sean Smith talks Proactive London's Andrew Scott through their 2019 results and current trading.
The company reported product sales of £1.7mln in 2019, 3% higher than the prior year.
He says the year ahead is about building on the sales achieved in the territories where it received approvals during 2019 and early 2020.
Smith's also expecting US regulators to approve Cedroz and its Mevalone product this year, although the pace of approvals has been slowed by the coronavirus (COVID-19) pandemic.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Eden Research PLC named herein, including the promotion by the Company of Eden Research PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE